Patent cliffs arent just a legal eventtheyre a supply-chain stress test.
If youre responsible for procurement, planning, manufacturing, or commercial operations in life sciences, the phrase patent cliff can sound like a headline. But in practice, its a…

Most patent searches miss the real story.
If youve ever relied on keyword searches to find prior art, you already know the uncomfortable truth: the most important references often arent hiding behind the words youre looking for. Theyre hiding behind …

How to Design Around Competitor Formulation Patents (Without Blowing Up Your IP Strategy)
In pharma, innovation is rarely just about the molecule. Its about the formulationthe way a drug is delivered, stabilized, absorbed, and manufactured. And thats e…

Formulation Forensics: The Hidden Clues Inside Drug Patent Claims
Drug patents are often treated like black boxesdense legal language, technical jargon, and a lot of trust us ambiguity. But if you know where to look, those claims can read like a detect…

The Biosimilar Patent Dance Isnt a Game of LuckIts a Game of Timing, Leverage, and Record-Building
If youre a biologics company or a biosimilar applicant, you already know the script: patents get listed, notices get served, motions get filed, andsomewh…

Generic winners dont wait for exclusivitythey engineer it.
In the Paragraph IV world, the 180-day exclusivity clock isnt just a deadline. Its a strategic assetone that can be won, preserved, and monetized only if the generic manufacturer treats litig…

The Patent Dance Is No Longer a ChoreographyIts a Competitive Weapon
If youre a biologics or biosimilar applicant, you already know the patent dance isnt just proceduralits strategic. But too many teams still treat it like a compliance checklist: excha…

Big Pharma loves to talk about pipelines. But the real forecasting edge is hiding in the supply chaininside the unglamorous, spreadsheet-heavy world of drug patent data.
Heres the uncomfortable truth: most demand forecasts are built on whats already se…

Patent cliffs arent just a legal eventtheyre a supply-chain inflection point.
For years, pharma teams have treated patent expiry data as a compliance artifact: something to track, report, and file away. But the companies that win in the next cycle ar…

Generic drug makers are facing a squeeze that doesnt look like a typical pricing pressure story. Its more like a slow-motion squeezeone where multiple forces hit at once: patent cliffs, tougher regulatory hurdles, reimbursement headwinds, supply-chain …